The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 1 March 2016 at 14:47 under RNS No 6696Q.
Dr M Slaoui's number of ADS withheld to meet tax liabilities changed from 13,804
All other details remain unchanged.
The full amended text is shown below.
GlaxoSmithKline plc
Notification of Transactions of Directors and Persons Discharging Managerial Responsibility
GlaxoSmithKline Deferred Annual Bonus Plan
Withholding of shares to meet tax liabilities
The table below sets out changes in the interests of an Executive Director and Person Discharging Managerial Responsibility (PDMR) in the American Depositary Shares (ADS) of GlaxoSmithKline plc arising from the withholding of ADSs at a fair market value of $39.14 per ADS (the closing price on 26 February 2016 which was the business day prior to vesting) to meet tax liabilities following the vesting of the pre-tax awards granted in 2013 under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (DABP). The awards vested on the third anniversary of the award date which was 28 February 2016.
|
Number of ADSs withheld to meet tax liabilities following the vesting of a DABP award |
Dr M Slaoui* |
11,083 |
Mr D Troy |
5,108 |
* Denotes an Executive Director
The Company, the Executive Director and PDMR were advised of these transactions on 29 February 2016.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
1 March 2016
